Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges

Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicina (Kaunas, Lithuania) Ročník 59; číslo 10; s. 1886
Hlavní autoři: Wen, Xiaofen, Coradduzza, Donatella, Shen, Jiaxin, Scanu, Antonio Mario, Muroni, Maria Rosaria, Massidda, Matteo, Rallo, Vincenzo, Carru, Ciriaco, Angius, Andrea, De Miglio, Maria Rosaria
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 01.10.2023
MDPI
Témata:
Biomarkers, Tumor - genetics
Biopsy
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical medicine
Clinical Relevance
Colorectal cancer
colorectal cancer (CRC)
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - genetics
Development and progression
Diagnosis
Disease
Humans
Japan
Metastasis
Minimal Residual Disease (MRD)
MRD clinical application in CRC
MRD techniques
Neoplasm, Residual - diagnosis
Oncology
Oncology, Experimental
Patients
Review
Serology
Tumors
Japan
colorectal cancer (CRC)
Minimal Residual Disease (MRD)
MRD techniques
MRD clinical application in CRC
ISSN:1648-9144, 1010-660X, 1648-9144
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina59101886